A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)-Reference-Cited by-同舟云学术

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

Published:2015-06-25 Issue:20 Volume:121 Page:3639-3648
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

von Minckwitz Gunter¹²,Conrad Bettina³,Reimer Toralf⁴,Decker Thomas⁵,Eidtmann Holger⁶,Eiermann Wolfgang⁷,Hackmann John⁸,Möbus Volker⁹,Marmé Frederik¹⁰,Potenberg Jochem¹¹,Stickeler Elmar¹²,Simon Eike¹³,Thomssen Christoph¹⁴,Huober Jens¹⁵,Denkert Carsten¹⁶,Alfer Joachim¹⁷,Jackisch Christian¹⁸,Nekljudova Valentina¹,Burchardi Nicole¹,Loibl Sibylle¹¹⁸,

Affiliation:

1. German Breast Group; Neu-Isenburg Germany

2. Department of Gynecology and Obstetrics; University Hospital Frankfurt; Frankfurt Germany

3. Elisabeth Hospital; Kassel Germany

4. Department Obstetrics and Gynecology; Sudstadt Clinic; Rostock Germany

5. Study Centre Oncology; Ravensburg Germany

6. Department of Gynecology and Obstetrics; University Hospital Kiel; Kiel Germany

7. Interdisciplinary Centre Munich; Munich Germany

8. Department of Obstetrics and Gynecology; Marienhospital; Witten Germany

9. Department of Obstetrics and Gynecology; Hoechst Clinic; Frankfurt Germany

10. University Women's Hospital; Heidelberg Germany

11. Department of Obstetrics and Gynecology; Ev. Waldkrankenhaus Hospital; Berlin Germany

12. University Women's Hospital; Freiburg Germany

13. Department of Obstetrics and Gynecology; Kreiskrankenhaus Torgau; Torgau Germany

14. University Women's Hospital; Halle Germany

15. University Women's Hospital; Ulm Germany

16. Berlin Charity Hospital, Institute of Pathology; Berlin Germany

17. Institute of Pathology Kaufbeuren-Ravensburg; Germany

18. Department of Gynecology Obstetrics and Gynecology; Sana Clinic; Offenbach Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29506/fullpdf

Reference14 articles.

1. Robert Koch Institut Cancer in Germany http://www.rki.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2013/krebs_in_deutschland_2013.pdf ?_blob=publicationFile 2015

2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials;Peto;Lancet.,2012

3. Undertreatment strongly decreases prognosis of breast cancer in elderly women;Bouchardy;J Clin Oncol.,2003

4. Survival of women after breast conserving surgery for early stage breast cancer;Du;Breast Cancer Res Treat.,2002

5. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials;Loibl;Breast Cancer Res.,2008

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment;Frontiers in Oncology;2023-12-15

2. Anthracyclines in the treatment of early breast cancer friend or foe?;The Breast;2022-10

3. Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review;European Journal of Cancer;2022-09

4. Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials;Frontiers in Endocrinology;2022-07-11

5. Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients;European Journal of Cancer;2022-05